Adaptated Physical Activity in Cancerology (APACAN)
APACAN study_Adaptated Physical Activity in Cancerology
This trial will measure the fatigue in breast cancer patients.
Two groups of patients will be realised:
- Arm A: Physical activity during treatment
- Arm B: No physical activity during treatment but after
The aim of the study is to decrease fatigue, with adequate physical activity, in primary breast cancer patients who receive a treatment for their pathology.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
This is an open monocentric study, randomized in two parallel arms with a waiting list.
The duration of the physical activty will vary according to the duration of the treatment: from 2 to 6 months.
Several questionnaries (fatigue, quality of life, ...) will be given to patients at the inclusion, at the end of the period of treatment and 3 to 6 months after the end of treatment.
One hundred patients are necessary in this study (fifty in each arm). We expect to a stability of the fatigue in Arm A compared to an increase of the fatigue in arm B.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Ikke aktuelt
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Women aged 18 to 75 years (included)
- Patient with a breast tumor, regardless of the stage and size (except metastatic patients)
- Patient with a local recurrence of breast cancer
- Patient with a second non-metastatic breast cancer
- Breast cancer treated, regardless of the surgery, at least by radiotherapy, chemotherapy (neoadjuvant or adjuvant) +/- targeted therapy
- A mandatory social security affiliation.
- Obtaining informed consent in writing, signed and dated.
- Medical certificate of fitness to practice physical (issued by the medical oncologist)
Exclusion Criteria:
- Cancer other than breast cancer and / or associated with breast cancer
- Metastatic Cancer
- in case of surgery before treatment, delay before beginning treatment inferior to 1 month post-surgery
- Men
- Woman pregnant
- Patient with cognitive or psychiatric disorders
- Patients suffering from disability
- Significant alterations in nutritional status (malnutrition with BMI <19, obese with BMI> 40, BMI)
- Cardiac contraindication to physical activity
- Knowledge and understanding of the French language enough not to learn the correct way of self-administered questionnaires or respond to questioning
- Participation in another clinical study with a similar objective
- Inability to reach the centers where physical activity takes place
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Annen: Arm A with physical activity during the treatment
In the arm A, patients will realise physical activity during the treatment.
Blood samples will be realised.
Questionnaries will be given to the patients.
|
Patients will realise physical activity either during their treatment, either after their treatment.
They will have practise a physical activity three times per week.
|
|
Annen: Arm B with physical activity after the treatment
In the arm B, the physical activity will be realised after treatment.
Blood samples will be realised.
Questionnaries will be given to the patients.
|
Patients will realise physical activity either during their treatment, either after their treatment.
They will have practise a physical activity three times per week.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Difference between the questionnaries scores MFI 20 (specific fatigue) between baseline and end of treatment.
Tidsramme: up to 6 months
|
The scores of fatigue at the end of treatment and at the inclusion will be compared.
|
up to 6 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
QLQ-C30
Tidsramme: up to 6 months
|
Comparison of the scores of QLQ-C30 assessed at the end of the treatment and at the inclusion.
|
up to 6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Yves Jean Bignon, MD,PhD, Centre Jean Perrin
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 2014-A00091-46
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .